

**Technology Available for Industry-Academia Collaboration or Technology
Licensing. “Development of Antivirals Against Flaviviruses and
Paramyxoviruses”
Date: 2026. 07. 27**

1. Title:

NHRI technology, “**Development of Antivirals Against Flaviviruses and Paramyxoviruses**” (abbreviated as “**The Technology**”) available for industry-academia collaboration or technology licensing.

2. Description:

Emerging and re-emerging viral diseases continue to threaten global public health. Rapidly deployable technologies for antiviral discovery and evaluation are therefore important for research preparedness. Paramyxoviruses include multiple medically important pathogens, and viral replication proteins and mechanisms provide potential targets for therapeutic intervention. NHRI has established research capabilities in virology, molecular biology, viral replication, and antiviral candidate evaluation, and continues to develop research and screening platforms for assessing inhibition of viral replication. These technologies may support the evaluation of candidate compounds and the development of broad-spectrum antiviral agents. NHRI invites qualified partners to pursue industry-academia collaboration or technology licensing in this field.

3. Potential collaboration partner qualifications:

- (1) be incorporated and approved by law and does not have any record of misconduct or conviction for any offense.
- (2) better to have related experience and skills for developing “**The Technology**”
- (3) better to have experience of international collaboration and clinical trial.
- (4) better to be ready to invest or be able to raise the funds.

4. Registration :

Please contact to Ms. Wan-Ping Hsieh (Address: Technology Transfer and Incubation Center, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 35053, Taiwan, R.O.C., Tel: +88637-246166 # 33227, E-mail: wanping@nhri.edu.tw).

5. Other:

- (1) NHRI retains the right to modify and terminate this announcement.
- (2) If **The Technology** has been exclusively licensed, this announcement will automatically invalid.
- (3) For detailed status of **The Technology**, please contact to the case officer.

Attachments:

I: Announcement

II: Industry-Academia Collaboration Proposal

III: Licensing Proposal